Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: vorinostat

« Back to Dashboard

Summary for Generic Name: vorinostat

Drug Master File Entries: see list2
Suppliers: see list1
Therapeutic Class:Antineoplastics

Pharmacology for Ingredient: vorinostat

Clinical Trials for: vorinostat

Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
Status: Not yet recruiting Condition: Mantle Cell Lymphoma

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Status: Completed Condition: Multiple Myeloma

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Status: Active, not recruiting Condition: Brain Metastases

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
Status: Terminated Condition: Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma

Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)
Status: Active, not recruiting Condition: Multiple Myeloma

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
Status: Recruiting Condition: Malignant Solid Tumour

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Status: Completed Condition: Lymphoma

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Status: Recruiting Condition: Advanced Cancers

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
Status: Active, not recruiting Condition: Adult Solid Neoplasm

Vorinostat Plus Radiation Therapy in Pancreatic Cancer
Status: Terminated Condition: Pancreatic Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
CAPSULE;ORAL021991Oct 6, 2006RXYes8,067,472<disabled><disabled>
CAPSULE;ORAL021991Oct 6, 2006RXYes8,101,663<disabled><disabled>
CAPSULE;ORAL021991Oct 6, 2006RXYes<disabled><disabled>
CAPSULE;ORAL021991Oct 6, 2006RXYes7,851,509<disabled>Y<disabled>
CAPSULE;ORAL021991Oct 6, 2006RXYes7,399,787<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn